MINNEAPOLIS, Nov. 13, 2008 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (NasdaqGM:VASC - News) today announced that it has once again been included on the 2008 Deloitte Technology Fast 500, a ranking of the 500 fastest growing technology companies in North America. Rankings are based on percentage revenue growth over five years, from 2003-2007.

Vascular Solutions' CEO, Howard Root, commented: ``This is the fifth year that we have been ranked as one of the 500 fastest growing technology companies in North America, which is a testament to the continued dedication and hard work of our employees. It is especially pleasing to be able to achieve our 346% revenue growth over the past five years through advancing our mission of delivering excellence in vascular devices. We are honored to be one of just three Minnesota companies on the Deloitte's Technology Fast 500 list for 2008.''

``Each company on Deloitte's Technology Fast 500 is an innovator with an exceptional five-year track record of growth,'' said Phil Asmundson, Deloitte LLP Vice Chairman and National Managing Partner for Technology, Media and Telecommunications. ``Vascular Solutions has earned its position among the fastest growing companies in North America, and we congratulate their important accomplishment.''

About Vascular Solutions

Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within vascular procedures. The company's five product categories consist of hemostat (blood clotting) products, extraction (clot removal) catheters, vein products, specialty catheters and access products. Over 90% of the company's revenues are from products that were initially launched within the last five years.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2007 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of sustained profitability, exposure to intellectual property claims, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to http://www.vascularsolutions.com.

About Deloitte

As used in this document, ``Deloitte'' means Deloitte LLP. Please see http://www.deloitte.com/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

          Vascular Solutions, Inc.
          Howard Root, CEO
          James Hennen, CFO
          (763) 656-4300